A second GLP1R/GIPR coagonist, tirzepatide (previously called LY3298176, marketed as Mounjaro® for T2D and Zepbound® for obesity, Eli Lilly) is a 39-amino acid peptide acylated at the lysine 20 residue with a C20 fatty diacid. The gene discussed is GIPR; the disease is obesity disorder.